School of Medicine

Pulmonary/Critical Care

Bronchiectasis & NTM Program

 

At LSU Health New Orleans, within our section of Pulmonary/Critical Care Medicine & Allergy/Immunology, we're committed to advancing the care and outcomes for individuals grappling with bronchiectasis and nontuberculous mycobacteria (NTM) infections. These conditions disrupt the airways' ability to expel mucus, impacting lung function and susceptibility to infections.

Our multidisciplinary approach involves a collaborative team focused on optimizing chest health. Leveraging our collective expertise and research insights, we tailor personalized treatment strategies to enhance the quality of life and longevity for each patient.

Our Team

Our team of physicians, researchers, nursing staff, respiratory therapists, research coordinators, and others work together to provide direct care to our patients, as well as to advance scientific and medical knowledge about bronchiectasis and nontuberculous mycobacterial infections. 

 

macrae

Shelby MacRae, MD

Director NTM-Bronchiectasis Program
smacra@lsuhsc.edu

 

 

ali

Juzar Ali, MD

Consultant Director NTM-Bronchiectasis Program

 

shellito

Judd Shellito, MD

Clinical Trials Director NTM-Bronchiectasis Program

 

wolfe

Amy Wolfe, MD

Director, LSUHSC-Wetmore TB Clinic and Post-TB Bronchiectasis

 

korah-sedgwick

Michelle Korah-Sedgwick, MD

zea

Arnold Zea, PhD

welsh

David Welsh, MD
 
Marie Sandi, RN, BSN, APRN-C

Clinical Trials Coordinator

 

Paula Lauto, RN, BSN

Clinical Research Nurse

 

Bianca Robinson, MSN, RN

Lead Clinic Nurse

Anjel Guitroz, BS

Clinical Research Associate

 

Priyanka Jadhav, PhD

Research Associate

 

Shandrica Seymour-Adams, BSHIM

Clinical Navigator

Our Clinic

Our clinic is located on the second floor of the University Medical Center Clinic Building.

To inquire about appointments please call our nurse lead Bianca at 504-702-4574, reach out to us via email at bronchiectasis@lsuhsc.edu, or call 504-702-5700. 

At University Medical Center through LCMC Health, we provide laboratory testing, pulmonary function testing, imaging testing, as well as consulting services with necessary consultants, such as Otolaryngology (ENT), Gastroenterology (GI), Thoracic Surgery.

Research Program

The Mission of the Research Component of the LSU Health NTM-Bronchiectasis Program ​

To contribute new knowledge to the biological, clinical, and epidemiological scientific domains relevant to the health of patients with bronchiectasis by maintaining a sustainable, multifaceted, multilevel portfolio of clinical and translational research on bronchiectasis.​

  • BE-Frail: Chronic Suppurative Lung Disease, the Microbiota, and Frailty

  • Bronchiectasis Research Registry 

  • Nontuberculous Mycobacterium Clinical Database & Biospecimen Bank

  • MAC 2v3-Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease

  • PARATEK-A Phase 2, double-Blind, Randomized, parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)

  • EBO-301-A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lund Disease (MACrO2)

  • RENOVION-A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough

  • ASPEN-A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis

  • ENCORE-A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

  • MAC-CLOFAZIMINE-001 Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease

  • Post trial Access (PTA) Program for Brensocatib (WILLOW and ASPEN)

  • Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infection 

  • ARISE-A randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lund Infection Caused by Mycobacterium avium Complex (MAC)

  • WILLOW- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis

  • INS 212-A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (AMC) that are refractory to treatment

  • INS 312-An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment

Patient Information and Resources

 

What is Bronchiectasis?

What is Nontuberculous Mycobacteria?

What are Airway Clearance Techniques?

 

We are committed to supporting our patients in addition to providing medical care. Look out for our Patient Support Group which we plan to re-start soon.